About Scorpion Therapeutics
Scorpion Therapeutics develops precision oncology treatments aimed at targeting specific cancer drivers. Their approach involves creating drugs that interact with validated cancer targets, enhancing their selectivity and safety to improve treatment efficacy. Unlike many competitors, Scorpion Therapeutics focuses on forming partnerships with larger pharmaceutical companies for the distribution of their drugs, allowing them to concentrate on research and development. Their goal is to provide effective cancer treatments that can make a significant impact on patients' lives.
Boston, MassachusettsHeadquarters
2020Year Founded
$408.5MTotal Funding
SERIES_CCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Risks
Leadership changes may impact strategic direction and company morale.
Over-reliance on partnerships could limit Scorpion's control over product distribution.
Intense competition in precision oncology may affect Scorpion's market share.
Differentiation
Scorpion Therapeutics specializes in precision medicine for cancer, focusing on small-molecule drugs.
Their Precision Oncology 2.0 strategy aims to redefine cancer treatment with targeted therapies.
Scorpion's STX-478 and STX-721 are designed as potentially best-in-class cancer inhibitors.
Upsides
Scorpion raised $150M in Series C funding, boosting their oncology pipeline development.
Partnership with Pierre Fabre expands Scorpion's market reach in Europe and China.
Growing demand for precision oncology aligns with Scorpion's targeted therapy focus.
Funding
Total raised$408.55 M
Latest valuation$750.00 M
StageSERIES_C
SERIES A
9/30/2020$108
$540.00 M